Eli Lilly said on May 27 the company received a subpoena from the U.S. Department of Justice related to the New Jersey plant that makes the Covid-19 treatment, bamlanivimab.

Based in South San Francisco, Lyell Pharmaceuticals filed for an initial public offering (IPO) with plans to raise $150 million. The preclinical biotech raked in $493 million in a Series C round on March 12, 2020. 

After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.

Building on the success of the company’s mRNA research, BioNTech will establish its first regional hub in the Asia Pacific region. The company will open a state-of-the-art manufacturing facility to support a global supply of mRNA-based vaccines and therapeutics in Singapore.

Pfizer reported first-quarter 2021 revenue of $14.6 billion, an impressive 42 percent operational growth. The company’s Covid-19 vaccine revenue accounted for $3.5 billion of the total.

Johnson & Johnson is establishing a vaccine supply network in which 10 manufacturing sites would be involved in the production of the company’s Covid-19 vaccine, in addition to J&J’s plant in Leiden, the Netherlands.

The U.S. Food and Drug Administration requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson Covid-19 vaccine at their facility in Baltimore.

The United States put Johnson and Johnson in charge of a plant that ruined 15 million doses of the company’s Covid-19 vaccine and stopped British drugmaker AstraZeneca from using the facility, a senior health official said on April 3.

New York City-based Pfizer announced plans to create a professional services office in Tampa, Florida and a major construction project in Portage, Michigan.

Novartis is closing a manufacturing facility in Longmont, Colorado acquired by company subsidiary AveXis during 2019 that has provided additional production capacity for Zolgensma, a gene therapy treatment for spinal muscular atrophy.